Compare IDEXX Laboratories, Inc. (IDXX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Procter & Gamble Co — how do they compare? IDEXX Laboratories, Inc. trades at $571.6 (market cap $46.22B), while Procter & Gamble Co trades at $144.43 (market cap $337.53B). The key difference: Procter & Gamble Co is far larger — about 7.3× IDEXX Laboratories, Inc.'s market cap, and Procter & Gamble Co pays a 3% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PG | |
|---|---|---|
Market Cap | $46.22B | $337.53B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $167.18 |
52-Week Low | $526.44 | $138.10 |
Enterprise Value | $47.12B | $363.37B |
Volume | — | 6,423,436 |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Procter & Gamble (PG) trades at $144.35, down 1.39% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $84.28B for 2025 with a net income margin of 18.44%, and has beaten EPS estimates in recent quarters. Analyst consensus is a Buy with a $161.20 price target, though recent news highlights concerns over its premium valuation amid modest growth expectations.
PG offers stable fundamentals and a strong dividend history, but faces risks from competitive pressures and economic sensitivity. The stock's near-term upside may be capped by its high P/E of 21.94, while long-term investors could benefit from its consistent profitability and brand strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
